Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | The challenges associated with long-term TKI use in patients with CML

Mhairi Copland, MB ChB, PhD, University of Glasgow, Glasgow, UK, shares some insights into the challenges associated with the long-term use of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML) and strategies to overcome these. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


M.C. has received research funding from Cyclacel and Incyte, is/has been an advisory board member for Novartis, Incyte, Jazz Pharmaceuticals, Pfizer and Servier, and has received honoraria from Astellas, Novartis, Incyte, Pfizer and Jazz Pharmaceuticals.